292 related articles for article (PubMed ID: 23590229)
21. Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy.
Worodria W; Massinga-Loembe M; Mazakpwe D; Luzinda K; Menten J; Van Leth F; Mayanja-Kizza H; Kestens L; Mugerwa RD; Reiss P; Colebunders R;
J Acquir Immune Defic Syndr; 2011 Sep; 58(1):32-7. PubMed ID: 21654499
[TBL] [Abstract][Full Text] [Related]
22. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
Siegfried N; Uthman OA; Rutherford GW
Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008272. PubMed ID: 20238364
[TBL] [Abstract][Full Text] [Related]
23. High Rates of Drug-induced Liver Injury in People Living With HIV Coinfected With Tuberculosis (TB) Irrespective of Antiretroviral Therapy Timing During Antituberculosis Treatment: Results From the Starting Antiretroviral Therapy at Three Points in TB Trial.
Naidoo K; Hassan-Moosa R; Mlotshwa P; Yende-Zuma N; Govender D; Padayatchi N; Abdool-Karim SSS
Clin Infect Dis; 2020 Jun; 70(12):2675-2682. PubMed ID: 31622456
[TBL] [Abstract][Full Text] [Related]
24. Impact of ART on TB case fatality stratified by CD4 count for HIV-positive TB patients in Cape Town, South Africa (2009-2011).
Kaplan R; Caldwell J; Middelkoop K; Bekker LG; Wood R
J Acquir Immune Defic Syndr; 2014 Aug; 66(5):487-94. PubMed ID: 24820105
[TBL] [Abstract][Full Text] [Related]
25. Reduction of HIV-associated excess mortality by antiretroviral treatment among tuberculosis patients in Kenya.
Onyango DO; Yuen CM; Cain KP; Ngari F; Masini EO; Borgdorff MW
PLoS One; 2017; 12(11):e0188235. PubMed ID: 29145454
[TBL] [Abstract][Full Text] [Related]
26. Duration of anti-tuberculosis therapy and timing of antiretroviral therapy initiation: association with mortality in HIV-related tuberculosis.
Cortes CP; Wehbe FH; McGowan CC; Shepherd BE; Duda SN; Jenkins CA; Gonzalez E; Carriquiry G; Schechter M; Padgett D; Cesar C; Madero JS; Pape JW; Masys DR; Sterling TR;
PLoS One; 2013; 8(9):e74057. PubMed ID: 24066096
[TBL] [Abstract][Full Text] [Related]
27. Prevention of Early Mortality by Presumptive Tuberculosis Therapy Study: An Open Label, Randomized Controlled Trial.
Manabe YC; Worodria W; van Leth F; Mayanja-Kizza H; Traore AN; Ferro J; Pakker N; Frank M; Grobusch MP; Colebunders R; Cobelens F
Am J Trop Med Hyg; 2016 Dec; 95(6):1265-1271. PubMed ID: 27928077
[TBL] [Abstract][Full Text] [Related]
28. A Markov model for the effects of virological failure on HIV/AIDS progression in tuberculosis co-infected patients receiving antiretroviral therapy in a rural clinic in northern South Africa.
Shoko C; Chikobvu D; Bessong PO
S Afr Med J; 2020 Mar; 110(4):313-319. PubMed ID: 32657744
[TBL] [Abstract][Full Text] [Related]
29. Earlier initiation of antiretroviral therapy, increased tuberculosis case finding and reduced mortality in a setting of improved HIV care: a retrospective cohort study.
Hermans SM; van Leth F; Manabe YC; Hoepelman AI; Lange JM; Kambugu A
HIV Med; 2012 Jul; 13(6):337-44. PubMed ID: 22296211
[TBL] [Abstract][Full Text] [Related]
30. Predictors of Mortality among Tuberculosis/HIV-Coinfected Persons in Southwest Ethiopia: A Case-Control Study.
Deribe K; Yami A; Deribew A; Mesfin N; Colebunders R; Van Geertruyden JP; Woldie M; Maja T
J Int Assoc Provid AIDS Care; 2015; 14(3):269-73. PubMed ID: 23966102
[TBL] [Abstract][Full Text] [Related]
31. Delays in starting antiretroviral therapy in patients with HIV-associated tuberculosis accessing non-integrated clinical services in a South African township.
Lawn SD; Campbell L; Kaplan R; Little F; Morrow C; Wood R;
BMC Infect Dis; 2011 Sep; 11():258. PubMed ID: 21957868
[TBL] [Abstract][Full Text] [Related]
32. [Impact of etiotropic therapy on the immune status of patients with HIV infection and tuberculosis].
Zimina VN; Kravchenko AV
Ter Arkh; 2015; 87(11):37-41. PubMed ID: 26821414
[TBL] [Abstract][Full Text] [Related]
33. The effect of incident tuberculosis on immunological response of HIV patients on highly active anti-retroviral therapy at the university of Gondar hospital, northwest Ethiopia: a retrospective follow-up study.
Assefa A; Gelaw B; Getnet G; Yitayew G
BMC Infect Dis; 2014 Aug; 14():468. PubMed ID: 25164855
[TBL] [Abstract][Full Text] [Related]
34. The effect of complete integration of HIV and TB services on time to initiation of antiretroviral therapy: a before-after study.
Kerschberger B; Hilderbrand K; Boulle AM; Coetzee D; Goemaere E; De Azevedo V; Van Cutsem G
PLoS One; 2012; 7(10):e46988. PubMed ID: 23071690
[TBL] [Abstract][Full Text] [Related]
35. Impact of Latent M. tuberculosis Infection Treatment on Time to CD4/CD8 Recovery in Acute, Recent, and Chronic HIV Infection.
Grinsztejn E; Cardoso SW; Velasque L; Hoagland B; Dos Santos DG; Coutinho C; Cruz Silva SDC; Nazer SC; Ferreira ACG; Castilho J; Grinsztejn B; Veloso VG
J Acquir Immune Defic Syndr; 2023 Dec; 94(4):355-363. PubMed ID: 37595204
[TBL] [Abstract][Full Text] [Related]
36. Incidence and mortality of tuberculosis before and after initiation of antiretroviral therapy: an HIV cohort study in India.
Alvarez-Uria G; Pakam R; Midde M; Naik PK
J Int AIDS Soc; 2014; 17(1):19251. PubMed ID: 25499123
[TBL] [Abstract][Full Text] [Related]
37. Demographic and clinical factors correlated with clinical outcomes among people with HIV treated by antiretroviral therapy: a retrospective cohort study.
Li Y; Liu H; Zhang S; Zhang Y; Wang H; Zhang H; Li X
BMC Infect Dis; 2024 May; 24(1):514. PubMed ID: 38778273
[TBL] [Abstract][Full Text] [Related]
38. Estimation of mortality among HIV-infected people on antiretroviral treatment in East Africa: a sampling based approach in an observational, multisite, cohort study.
Geng EH; Odeny TA; Lyamuya RE; Nakiwogga-Muwanga A; Diero L; Bwana M; Muyindike W; Braitstein P; Somi GR; Kambugu A; Bukusi EA; Wenger M; Wools-Kaloustian KK; Glidden DV; Yiannoutsos CT; Martin JN
Lancet HIV; 2015 Mar; 2(3):e107-16. PubMed ID: 26424542
[TBL] [Abstract][Full Text] [Related]
39. Time to eligibility for antiretroviral therapy in adults with CD4 cell count > 500 cells/μL in rural KwaZulu-Natal, South Africa.
McGrath N; Lessells RJ; Newell ML
HIV Med; 2015 Sep; 16(8):512-8. PubMed ID: 25959724
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults.
Bisson GP; Ramchandani R; Miyahara S; Mngqibisa R; Matoga M; Ngongondo M; Samaneka W; Koech L; Naidoo K; Rassool M; Kirui F; Banda P; Mave V; Kadam D; Leger P; Henestroza G; Manabe YC; Bao J; Kumwenda J; Gupta A; Hosseinipour MC;
AIDS; 2017 Oct; 31(16):2217-2225. PubMed ID: 28742529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
